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Abstract: Psoriatic arthritis (PsA) is a chronic inflammatory arthropathy associated with 
psoriasis (PsO). PsA could be considered an enthesal disease because of the link between 
mechanical stress (entheses) and immunologically active tissue (synovium). Evidence of efficacy 
of anti-tumor necrosis factor alpha (TNF-α) is supported by reduction of histological vascularity 
and immune cell infiltrates in synovial tissue after treatment. Certolizumab pegol (CZP) is a 
polyethylene glycolylated (PEGylated) Fab′ fragment of a humanized monoclonal antibody that 
binds and neutralizes human TNF-α. The PEG moiety of the Fab fragment, markedly increases 
the half-life of CZP and confers to the drug a unique structure that differs from the other anti-
TNF-α agents tested for the treatment of Crohn’s disease, rheumatoid arthritis, ankylosing 
spondylitis, axial spondyloarthritis, nonradiographic spondyloarthritis, PsO, and PsA. In contrast 
to other anti-TNF-α agents, CZP did not mediate increased levels of apoptosis, suggesting that 
these mechanisms are not essential for the anti-TNF-α efficacy in Crohn’s disease. As CZP, 
infliximab, and adalimumab, but not etanercept, almost completely inhibited lipopolysaccharide-
induced interleukin-1 beta release from monocytes, this cytokine-production inhibition may 
be relevant for drug efficacy. Due to these characteristics, it has been demonstrated in clinical 
studies that CZP effectively improves signs and symptoms of arthritis and physical function 
and skin manifestations of PsO, with a safety profile similar to rheumatoid arthritis. This drug 
can be considered as a valid treatment in patients affected by PsA. The efficacy and tolerability 
profiles suggest CZP as a suitable antipsoriatic drug in the treatment of PsA.
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Introduction
Psoriatic arthritis (PsA) is a chronic inflammatory arthropathy commonly associated 
with psoriasis (PsO). Several epidemiologic studies have examined the association 
between PsO and inflammatory arthritis. In studies performed in outpatients suffering 
from PsO, arthritis prevalence varied from 6% to 39%.1 Joint disease is characterized 
by systemic inflammation and extensive synovitis, resulting in erosions of articular 
cartilage leading to joint destruction. Progressive damage begins early in the course 
of the disease as a consequence of the active inflammation, and results in radiological 
damage in up to 47% of patients at a median interval of 2 years, causing irreversible 
disability.2 PsA belongs to the spondyloarthritis (SpA) group and affects primarily the 
peripheral joints, the spine, and the entheses. The pathogenesis of PsA is linked to innate 
immune response that generates high concentrations of inflammatory cytokines, such 
as tumor necrosis factor alpha (TNF-α), which promotes effector function of a variety 
of tissue cells and thereby sustains the chronic inflammation leading to synovitis in 
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PsA.3 Overexpression of TNF-α is believed to play a key role 
in the pathogenic mechanisms linking PsO and arthritis.4 This 
cytokine has been implicated in a number of inflammatory 
diseases, including PsA, by inducing the production of other 
inflammatory cytokines such as interleukin (IL)-1 and IL-6, 
chemokines like IL-8, and degradative enzymes, including 
several matrix metalloproteinases.5 Moreover, it mediates a 
number of biological processes that can result in joint damage 
characterized by stimulation of bone resorption and inhibition 
of bone formation and of synthesis of proteoglycans. TNF-α 
may also contribute to vascular proliferation, which is 
probably one of the key and earlier observable changes in 
psoriasis and PsA.6 Therapies neutralizing pivotal cytokines 
might not only limit joint damage and skin inflammation 
but also reduce the incidence of adverse metabolic and 
cardiovascular events in affected patients.7 Several trials 
have shown excellent clinical results with anti-TNF-α agents, 
etanercept,8 infliximab,9 adalimumab,10 and golimumab.11 
These agents have been proven to be effective in different 
aspects of the disease, including skin lesions, joint pain 
and swelling, enthesitis, and dactylitis, resulting in a 
significant improvement both in mobility and in radiographic 
progression and quality of life (QoL) parameters.12 Recently, 
certolizumab pegol (CZP) has been tested and evaluated 
for several inflammatory diseases, and for its safety and 
efficacy profiles. This drug can also be considered for 
the treatment of PsA. In this review, we investigated the 
pathogenetic roles of TNFα in inflammatory arthritis as 
PsA, and the mechanisms of action of CZP. In particular, 
the evidence of efficacy of CZP in PsA will be explored.
Pathogenesis of PsA: link 
with TNF-α
Although the biological function of TNF-α is not completely 
clear in both normal and pathological conditions, elevated 
levels of TNF-α have been found in patients experiencing 
inflammatory diseases, and clinical data on the efficacy of 
TNF-α-blocking agents suggest that it plays a key role in 
the pathogenesis of various inflammatory disorders such as 
Crohn’s disease (CD), rheumatoid arthritis (RA), and SpA, 
as well as PsO and PsA.13 PsA pathogenesis is incompletely 
understood, and a pathophysiological role of the synovium 
has been recently suggested. Some authors consider PsA as 
an enthesal disease linking mechanical stress (entheses) to 
immunologically active tissue (synovium).4 A dermatological 
perspective brings an alternative view of autoimmunity 
that could partly explain the role of innate immunity. The 
skin may likely secrete proinflammatory mediators, such 
as TNF-α, to the affected proximal or distant joints, and 
the interruption of this pathological communication may 
represent a therapeutic target14 (Figure 1). TNF-α produced 
by macrophage infiltration in synovial tissue may constitute 
the basis of synovium hypersensitization to endogenous 
ligands of the innate immune system.15 Synovial tissue 
analysis has been used in order to distinguish PsA from other 
inflammatory arthritis, particularly in terms of pathological 
aspects and response to synthetic or biological disease-
modifying antirheumatic drugs (DMARDs).16 Recent 
findings suggest an important feature of PsA synovium: 
the presence of lymphoid aggregates of variable size and 
organization, previously considered highly specific of RA 
while recently observed in other inflammatory arthritis as 
PsA. Two major cytokines are involved in the pathogenesis 
of lymphoid aggregates: TNF-α and lymphotoxin beta. 
They play a potential role in the development of the high 
endothelial venule phenotype and in the expression of homing 
chemokines. Moreover, increased levels of these cytokines 
have been demonstrated in PsA synovial fluid.17 It has been 
suggested that these structures linked to inflammatory 
cytokines may play a role in multiple processes, including 
antigen presentation, T-cell costimulation, and synthesis of 
soluble mediators.18 For this reason, TNF-α-targeting agents 
represent a valuable therapeutic approach in treating such 
disorders as PsA. There are five marketed agents targeting 
TNF-α that possibly have a complex mechanism of action 
beyond the plain TNF-α neutralization. They differ in 
structure, pharmacokinetic, and in vitro properties, all of 
which may have relevant therapeutic implications.
Treatment of PsA: evidence 
of anti-TNF-α efficacy
Few studies have focused on the correlation between 
clinical composite scores and changes in PsA synovium. 
Treatment with DMARDs can modify synovial cell 
populations and infiltrates, correlating with the clinical 
improvement observed in treated patients.19 One of the 
f irst studies establishing the eff icacy of anti-TNF-α 
in modifying synovial tissue in PsA showed reduced 
vascularity and suppression of immune cells after treatment 
with infliximab.20 In particular, the authors of this study 
evaluated the effects of anti-TNF-α treatment on histologic 
abnormalities of the synovium in patients with SpA in 
order to confirm a potential benefit on peripheral synovitis 
and to investigate the mechanism of action of anti-TNF-α 
agents. Histologic and immunohistochemical data showed 
a significant decrease in vascular cell adhesion molecule 1 
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expression on the synovial endothelium, a reduction in 
neutrophil and macrophage infiltration of the synovial 
sublining layer, and diminished presence of macrophage-
like synoviocytes. The aforementioned properties suggest 
that primarily anti-TNF-α agents act in deactivating the 
endothelium, with a decrease in vascularity, which in 
turn reduces migration and homing of inflammatory cells 
into the synovial tissue. Additionally, the thickness of the 
synovial lining was normalized after only 12 weeks of 
treatment. This effect is possibly mediated by a reduction 
in TNF-α-induced proliferation and/or restoration of Fas-
mediated apoptotic cell death of synovial fibroblasts.20 
Moreover, the number of CD55-positive synovial lining 
fibroblasts was significantly reduced at week 12. The most 
striking immunohistopathological changes included a 
reduction in lining layer thickness and in downregulation of 
hypervascularity and in endothelial activation, resulting in a 
decrease of the inflammatory cell infiltrate with differential 
effects on T and B cells.21 Kruithof et al demonstrated a 
significant reduction in CD3-positive cells in a cohort 
of PsA patients treated with adalimumab. Interestingly, 
a significant reduction in the number of CD3-positive cells 
was observed after only 4 weeks of treatment.22 Systemic 
modifications of the inflammatory process during anti-
TNF-α treatment concern mediators of inflammation. 
In fact, the evaluation of complement-system fragments 
in patients with PsA treated with anti-TNF-α agents 
showed a significant decrease in plasma C3 and C4 levels, 
independently from the anti-TNF-α used. Patients with good 
response showed a more pronounced reduction in serum 
TNFα, IL-1, IL-6
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Figure 1 Enthesal and Joint pathology in Psoriatic Arthritis. The origin of Inflammation in the enthesal complex in PsA is multifactorial. When stimulated by stress, infections 
and trauma (Koebner phenomenon), in a genetic background, fibroblast-like synoviocytes express selfDNA or/ and secrete inflammatory cytokines and MMPs. They produce 
complement system factors as C3 and C4 and express less CD59 during inflammation, who is an inhibitor of complement system activation. The activation of the complement 
system lead to the release of C5a and production of MAC with the lysis of cells and recruitment of immune cells. FLS secrete MCP-1 and IL-8 necessary for recruitment 
and activation of MΦ. Polyclonal activation of CD4+Tcells and Th17 is the consequence of the immunological synapse with DC linked to the binding with CD80/86 and 
CD28. When activate CD4+ Tcells produce: RANKL with activation of OC with the consequence of bone erosions and VEGF with the activation of endothelial cells and 
the formation of HEV 
Abbreviations: PsA (Psoriatic Arthritis); FLS (fibroblast-like synoviocytes); TNF (Tumor Necrosis Factor); MMP (Matrix metalloproteinases); MCP-1 (monocyte chemotactic 
protein-1); OC (Osteoclast); MΦ, (monocytes/macrophages); RANK/RANKL (Receptor activator of nuclear factor kappa-B/ ligand); MAC (membrane attack complex); VEGF 
(vascular endothelial growth factor); Th17 (T helper 17); DC (dendritic cell); CD (cluster differentiation).
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complement C3 levels as well as low baseline C3 levels. 
These findings underline that a reduction in complement 
native components may be considered as an improvement 
of a preexisting proinflammatory status reverted by anti-
TNF-α drugs. It could be postulated that persistently 
elevated C3 levels may represent a negative predictive 
factor influencing the outcome of anti-TNF-α therapy in 
RA and PsA. As a consequence, the detection of blood 
C3 levels may provide an additional tool in monitoring 
disease activity during treatment with anti-TNF-α in 
PsA patients.23 Recently, the Group for Research and 
Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) 
reported recommendations for PsA treatment.12 An 
excellent therapeutic improvement has been obtained by 
the introduction of biologic treatments designed to modify 
and regulate pivotal and specific mechanisms involved in 
PsO and PsA immunopathogenesis. To date, anti-TNF-α 
has been suggested to have a more favorable side-effect 
profile than synthetic DMARDs.24
Profile of certolizumab
Structural function
CZP (Cimzia; UCB, Brussels, Belgium) is a PEGylated 
(polyethylene glycol) Fragment antigen binding (Fab) 
of a humanized monoclonal antibody that binds and 
neutralizes human TNF-α. The structure of CZP differs 
significantly from the other agents that have undergone 
clinical evaluation. In vivo, the pharmacokinetic properties 
of Fab are limited. However, attachment of a 40 kDa PEG 
moiety to the Fab fragment markedly increases the half-life 
of CZP to a value comparable with that of a whole-antibody 
product, conferring to the drug a fast and lasting effect on 
the inhibition of joint damage and inflammation. The Fab 
fragment was engineered with a single free-cysteine residue 
in the hinge region, which enables site-specific attachment 
of PEG without affecting the ability of the Fab fragment 
to bind and neutralize TNF-α.26,27 The unique structure 
of CZP differs from that of other anti-TNF-α agents that 
have been tested for the treatment of CD, RA, ankylosing 
spondylitis (AS), axial SpA, nonradiographic SpA, PsO, 
and PsA. In fact, clinical efficacy of the drug reported in 
clinical trials highlighted the rapid improvement of CZP 
in signs and symptoms of inflammatory arthritis.
Mechanisms of action of CZP
Concerning the mechanism of action of this drug, it is not clear 
why CZP does not induce apoptosis of cells bearing TNF-
α, conversely to other anti-TNF-α agents. Hypothetically, 
in contrast to the other TNF-α-targeting drugs, CZP may 
bind to a different epitope compared to the other agents, 
which leads to a different intracellular signaling pattern. 
Increased apoptosis has been reported in tissue sections from 
affected bowel after 24 hours and 6 and 28 days of infliximab 
treatment.28 It is possible that the anti-inflammatory effect 
of infliximab indirectly induces apoptosis of activated cells. 
In this context, a series of comparative in vitro studies were 
conducted in order to explore the mechanism of action of CZP 
in CD. The mechanisms, including induction of apoptosis, 
antibody-dependent cell-mediated cytotoxicity (ADCC), 
and complement-dependent cytotoxicity (CDC), may not 
be required for clinical efficacy of an anti-TNF-α agent in 
CD, however, inhibition of bacterially stimulated cytokine 
production from macrophages may be needed for the function 
of an anti-TNF-α agent to produce efficacy. In fact, in contrast 
to the other anti-TNF-α agents tested, CZP did not mediate 
increased levels of apoptosis in any of the in vitro assays 
used, suggesting that these mechanisms are not essential for 
the efficacy of anti-TNF-α agents in CD. As CZP, infliximab, 
and adalimumab, but not etanercept, almost completely 
inhibited lipopolysaccharide-induced IL-1-β release from 
monocytes, this mechanism of inhibition of cytokine 
production may be important for efficacy of anti-TNF-α 
agents.29 Recently, Ueda et al investigated the cytotoxic 
effects of the anti-TNF-α agents CZP and golimumab.30 
Upon evaluation of their ability in binding to transmembrane 
TNF-α (tmTNF-α), and in inducing ADCC and CDC, both 
agents were proven effective in neutralizing tmTNF-α. In 
contrast to CZP, golimumab was also able to induce ADCC 
and CDC, similarly to infliximab and adalimumab. While 
CZP directly provoked nonapoptotic cell death in tmTNF-
α-expressing cells, golimumab generated a weaker apoptotic 
effect compared to infliximab and adalimumab. Accounting 
for these properties, the cytotoxic effects of anti-TNF-α 
agents on TNF-α-expressing cells underline their efficacy 
in treating granulomatous diseases.30 The direct cytotoxic 
effect of CZP on TNF-α-producing cells may contribute to 
the clinical effectiveness in the treatment of CD, whereas 
golimumab may be less effective for the treatment of 
granulomatous diseases.28,30
Intracellular signal transduction of CZP
Another important concern about the mechanism of action of 
CZP is the evidence of the intracellular signal transduction 
triggered by the drug. All available anti-TNF-α biologics 
have in common the capability to effectively neutralize 
TNF-α as a major pharmacological mechanism of action. 
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However, there are distinctions with respect to the effect of 
engagement with tmTNF-α. In all cases, anti-TNF-α biologics 
can act as antagonists by blocking interaction between 
tmTNF-α and TNFR1/2 (Tumor necrosis factor receptor 1/2) 
expressed on a responsive cell. A recent study reported similar 
ability of CZP, adalimumab, and infliximab in neutralizing 
mTNF-a-mediated (membrane Tumor necrosis factor-α 
mediated) signaling, whereas etanercept appeared to be about 
twofold less potent.31 However, in certain instances, an anti-
TNF-α may also act as an agonist through the phenomenon 
known as “reverse signaling,” in which the engagement of 
tmTNF-α leads to phosphorylation of specific serine residues 
in the cytoplasmic tail of tmTNF-α and a signal is transduced 
in the cell expressing tmTNF-α.32,33 Furthermore, regulated 
intramembrane proteolysis of tmTNF-α by signal peptide 
peptidase-like proteases is reported to release a TNF-α 
intracellular domain mediating reverse signaling in dendritic 
cells. The full significance of reverse signaling is unknown. 
One consequence of reverse signaling through tmTNF-α in 
activated human T cells by both etanercept and infliximab is the 
induction of E-selectin.34,35 However, by binding only a single 
TNF-α homotrimer, etanercept does not cross-link tmTNF-α 
(in the absence of rheumatoid factor), contrary to bivalent mAbs 
(monoclonal antibodies) such as infliximab. In this regard, it 
is interesting to highlight that infliximab, but not etanercept, 
suppresses T-cell proliferation by inducing G
0
/G
1
 cell-cycle 
arrest. Although the rheumatoid factor positively interferes in 
cross-linking etanercept to tmTNF-α, the suppression of cell 
proliferation is weakly observed, approximately half the level 
occurring with infliximab.36 Another possible consequence 
of reverse signaling induced by biologic anti-TNF-α relates 
to intracellular events and potential competition for shared 
signaling pathway molecules, in particular those induced 
by endotoxin-mediated TLR (Toll-like receptor)  signaling, 
given the observation that in vitro reverse signaling through 
tmTNF-α induces endotoxin resistance and suppression 
of cytokines, including TNF-α, IL-1β, IL-10, and IL-12.37 
Regarding cytokines, as mentioned above, various in vitro 
studies report that infliximab and/or adalimumab markedly 
suppress lipopolysaccharide-induced production of cytokines, 
including TNF-α, IL-1β, IL-10, and IL-12, as well as CZP 
whereas this does not occur with etanercept.28,38
First data on the efficacy of CZP
An interesting study performed by Nesbitt et al compared the 
biological effects of CZP to other anti-TNF-α agents.28 The 
different spectrum of biologic effects mediated by TNF-α has 
hampered efforts to define the mechanisms of action of these 
agents. Although CZP can bind to human polymorphonuclear 
cells no increase in cell death or release of myeloperoxidase 
was observed, possibly because of a difference in the way 
in which it signals through membrane mTNF. In contrast, 
the other three anti-TNF-α agents all induced both cell 
death and release of myeloperoxidase. In contrast with these 
biological differences between the drugs, no clinical studies 
were performed to compare the clinical efficacy between 
the five anti-TNF-α agents available. Actually, positive 
clinical outcomes from the PRECISE study on CZP in CD 
provided an opportunity to reassess available data from 
infliximab, adalimumab, and etanercept clinical trials.39,40 
CZP, infliximab, and adalimumab appear to be similar in 
terms of induction, maintenance of response, and remission, 
as reported in the PRECiSE40, ACCENT I (A Crohn’s Disease 
Clinical Trial Evaluating Infliximab in a New Long-term 
Treatment Regimen) and CHARM (Crohn's Trial of the Fully 
Human Antibody Adalimumab for Remission Maintenance) 
trials.41,42
Use of certolizumab in 
inflammatory arthritis: is there 
a rationale in psoriatic disease?
Distribution of CZP in inflamed tissues
The main feature of CZP is the distribution of the drug in 
inflamed tissues due to the effect of PEGylation. This aspect 
has been investigated using a noninvasive biofluorescence 
labeling methodology in murine arthritis.43 CZP, adalimumab, 
and infliximab distributed more effectively into inflamed 
tissue rather than noninflamed tissue. The penetration of CZP 
into arthritic paws was greater compared with adalimumab 
and infliximab, as was the duration of drug exposure in the 
inflamed tissue. These important features, characterizing 
CZP activity, may be attributed to the PEGylation and the 
smaller molecular weight. Exposure to a drug at the site of 
inflammation may be relevant in terms of efficacy for the 
treatment of inflammatory disorders such as inflammatory 
arthritis, namely RA and PsA. In this context, Palframan et al 
developed an in vivo methodology, enabled to measure 
antibody-type reagents in normal and inflamed tissue 
by detecting the distribution of TNF-α, using a novel 
noninvasive biofluorescence method.44 This technique 
indicated the ratio of penetration of CZP into inflamed 
arthritic paws compared with normal tissue was greater than 
that observed with adalimumab and infliximab. Furthermore, 
the duration of exposure in the inflamed versus normal tissue 
was more prolonged for CZP than for both adalimumab and 
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infliximab, and the accumulation of CZP in diseased tissue 
was more responsive to the severity of inflammation when 
compared with adalimumab and infliximab. These distinct 
structural features may affect efficacy, tolerability, rapidity, 
and/or sustainability of effect of CZP.45 In support of these 
findings, CZP was tested in inflammatory noninfectious 
diseases.
Clinical efficacy of CZP in active RA
Clinical efficacy of CZP in inflammatory arthritis – RA,46 
PsA,47 and SpA48 – was evaluated in several clinical trials 
(Table 1). However, the first clinical evidence comes from 
the use of CZP in the treatment of CD.39 Actually, in Europe, 
CZP in combination with methotrexate (MTX) is indicated 
for the treatment of moderate to severe active RA in adult 
patients when the response to DMARDs including MTX 
has been inadequate. CZP can be given as monotherapy in 
case of intolerance to MTX or when continued treatment 
with MTX is contraindicated.49 The drug has been shown to 
reduce the rate of progression of joint damage, as measured 
by X-ray, and to improve physical function when given in 
combination with MTX.50 Moreover, CZP was associated 
with a rapid, consistent clinical response in a diverse 
group of RA patients, including those with prior TNF-
α-inhibitor exposure in the Dose Flex dose-comparison 
trial.51 Dose Flex was a 34-week, phase IIIb, open-label, 
run-in, double-blind, placebo (PBO)-controlled randomized 
study in patients with active RA on stable-dose MTX. Of 
333 patients who entered the run-in, 53.5% had prior TNF-
α-inhibitor use. CZP demonstrated similar efficacy in RA 
patients with or without prior exposure to TNF-α inhibitors 
over 34 weeks of treatment. When CZP was withdrawn 
at week 16 in American College of Rheumatology 20 
(ACR20) responders, a greater maintenance of response 
in patients who had not previously been exposed to TNF-α 
inhibitors was observed. Moreover, a long-term safety 
study of 400 mg CZP for the treatment of RA was made 
with a period of observation of over 5 years.51 Patients in 
the FAST4 WARD trial52 were monitored for safety. The 
retention rates were reported up to week 280 (5.4 years) and 
safety results up to week 364. Adverse events (AEs) and 
serious AEs, as well as the number of serious infections, 
were similar between CZP and PBO; these findings were in 
the range of those reported for anti-TNF-α. Therefore the 
use of CZP 400 mg combination or monotherapy has been 
confirmed to have an acceptable long-term safety profile 
in line with what would be expected from an anti-TNF-α 
agent.52,53
Clinical efficacy of CZP 
and quality of life in SpA
Following the excellent results observed in patients affected 
by RA, as well as in patients affected by CD treated with CZP, 
the drug was tested in randomized clinical trials48,54 in SpA 
patients. Axial SpA (axSpA) is a form of SpA that includes 
both AS and nonradiographic axial SpA (nr-axSpA), as 
defined by the Assessment of Spondyloarthritis International 
Society criteria.55 Both subgroups of patients have been 
shown to have a similar burden on QoL. In particular, the 
effect of CZP on signs and symptoms of AS and nr-axSpA 
was evaluated in a 24-week, double-blind, randomized, PBO-
controlled phase III trial;54 325 patients were randomized. 
Baseline characteristics were similar between groups.54 
Improvements in the CZP-treated groups were observed 
in pain, fatigue, Bath Ankylosing Spondylitis Functional 
Index, and AS-QoL from the first measurement at week 1 
through to week 24 compared to PBO. Patients in the CZP-
treated arm had greater improvements in all the parameters 
studied compared to PBO. Improvements were also seen in 
the Medical Outcomes Study, the Short Form (36) Health 
Survey Mental Component Summary, and domains. CZP 
effectively improved patient-relevant outcomes in the broad 
population of axSpA patients classified using the Assessment 
of Spondyloarthritis International Society criteria.55 One of 
the main characteristics of SpA is the bone marrow edema 
of sacroiliac joints (SIJs) and spine, leading to chronic back 
pain. axSpA54 was the first report of the effect of CZP on 
inflammation of spine and SIJs in axSpA patients, including 
both AS and nr-axSpA patient populations, using magnetic 
resonance imaging (MRI). Moreover, improvements in 
Spondyloarthritis Research Consortium of Canada MRI, 
SIJ scores, and ankylosing spondylitis spine MRI score 
for activity, Berlin modifications, were observed in both 
CZP-dose arms compared to PBO overall and in both 
AS and nr-axSpA populations. Greater reductions in 
SIJ inflammation were observed for patient subgroups 
with ,5 years’ symptom duration, age , 45 years, and in 
males. In this clinical trial, CZP was effective in reducing 
inflammation in the SIJs and spine, as assessed by MRI 
in patients with axSpA, and in both AS and nr-axSpa 
populations.54
The application of CZP in PsO
Concerning PsO, CZP at an initial dose of 400 mg fol-
lowed by 200 or 400 mg every 2 weeks was evaluated in 
a randomized, PBO-controlled, double-blind study.56 The 
drug results were significantly more effective than PBO in 
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the treatment of patients with moderate to severe plaque 
psoriasis. Coprimary end points were $75% improvement 
from baseline in the Psoriasis Area and Severity Index 
(PASI 75) and a Physician’s Global Assessment (PGA) of 
clear–almost clear at week 12. A 75% decrease in PASI score 
was observed as early as the initial observation at week 2 in 
some CZP-treated patients. Therefore, CZP was well toler-
ated in patients with moderate to severe PsO, with a low 
incidence of injection-site pain or treatment discontinuation 
due to AEs.51 A retreatment extension study was conducted 
in 71 CZP PASI 75 responders who relapsed during a 12- 
to 24-week observation period without treatment. PASI 
75 was achieved by 75%, 83%, and 47% of patients in the 
CZP 200 mg, CZP 400 mg, and PBO groups, respectively 
(P , 0.001 for both treatment arms vs PBO). A PGA score 
of clear–almost clear was achieved by 53%, 72%, and 2%, 
respectively (P , 0.001 for both treatment arms vs PBO). 
In the retreatment study, median PASI scores were similar 
at week 12 in the first treatment and retreatment periods 
for both CZP groups. Serious AEs occurred in 3%, 5%, 
and 2% of CZP 200 mg, CZP 400 mg, and PBO patients, 
respectively. Treatment with CZP significantly improved 
psoriasis at week 12. Similar efficacy was observed at week 
12 in patients receiving retreatment for loss of response after 
drug withdrawal.56
Efficacy of CZP in PsA: rational 
use in psoriatic arthritis
Clinical and experimental findings suggest that CZP has 
a unique property of distribution in inflamed tissues. 
Moreover, in a recent paper of Shu et al, CZP was effective 
in inhibiting human dermal microvascular endothelial 
cell expression of angiogenic adhesion molecules and 
decreased human dermal microvascular endothelial cell 
angiogenic chemokine secretion.57 At the same time, CZP 
downregulated TNF-α-induced myeloid cell adhesion to 
endothelial cells and blocked leukocyte–endothelial cell 
adhesive interactions in RA synovial tissue, suggesting 
a novel role for CZP in blocking monocyte adhesion to 
inflamed synovial vasculature.57 In this regard, PsA can be 
considered as a systemic disease that involves not only skin 
and joints but also such other organs as enthesis, vascular 
endothelium, and adipocyte tissue. PsA synovial tissue is 
typically characterized by the presence of high endothelial 
venules associated with immune cell inf iltrates.16 
Concerning only joint and enthesis involvement, Mease 
et al experienced for the first time the clinical efficacy and 
safety of CZP in PsA (RAPID-PsA).47 Patients with active 
PsA who had failed $ 1 DMARD and could have failed 
# 1 anti-TNF-α were randomized PBO or CZP 400mg at 
week 0, 2 and 4 followed by either 200 mg CZP or 400 mg 
CZP. Patients receiving PBO who failed to achieve $10% 
decrease in tender-joint count and swollen-joint count 
at both weeks 14 and 16 were rescued and randomized 
at week 16 to receive CZP 200 mg or CZP 400 mg. 
The clinical primary end point was ACR20 response at 
week 12. A total of 409 patients were randomized with 
similar baseline demographic characteristics, and 20% of 
patients had previously failed an anti-TNF-α treatment. 
ACR20 response at week 12 was significantly higher 
in both CZP arms vs PBO. The majority of the overall 
response rate observed at week 24 was achieved by week 
12. Response with CZP was rapid, with a greater ACR20 
response as early as week 1 (7.4% for PBO vs 21.0% for 
CZP 200 mg [P = 0.001] and vs 23.0% for CZP 400 mg 
[P , 0.001]). At weeks 12 and 24, both CZP arms showed 
significantly greater improvements than PBO in ACR50 
and in ACR70. Greater improvements were also observed 
for both CZP arms in PASI 75, as well as in the Health 
Assessment Questionnaire Disability Index at week 24. 
AEs occurred at the rates of 68% vs 62% and serious 
AEs at 4% vs 7% in PBO vs CZP, respectively. The safety 
profile was similar to that observed with CZP in RA.47 
The authors concluded that CZP effectively improved the 
signs and symptoms of arthritis, physical function, and skin 
manifestations of PsO in patients with PsA, with a safety 
profile similar to RA.53 Other clinical values, like enthesitis 
and nail psoriasis, were considered in the ongoing 158-
week RAPID-PsA trial (double-blind and PBO controlled 
to week 24, dose-blind to week 48, and then open-label to 
week 158). In patients with enthesitis (64.3%), the Leeds 
Enthesis Index change from baseline at week 24 was -2.0 
with CZP 200 mg (P , 0.001) and -1.8 with CZP 400 mg 
(P , 0.003) vs -1.1 PBO. For patients with baseline nail 
disease (73.3%), Nail Psoriasis Severity Index change from 
baseline at week 24 was -1.6 with CZP 200 mg and -2.0 
with CZP 400 mg vs -1.1 PBO. No differences in Leeds 
Dactylitis Index change from baseline were observed in 
patients with baseline dactylitis.58 
Efficacy of CZP in radiographic 
progression in PsA
Furthermore, the efficacy of CZP was also evaluated in 
radiographic progression in PsA patients. Gladman and 
colleagues performed a 24-week patient-reported outcome, 
phase III, double-blind, randomized, PBO-controlled study. 
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Effect of CZP on the multiple facets of PsA included an 
analysis of changes from baseline of modified Total Sharp 
Score. CZP was efficacious in inhibiting radiographic 
progression compared to PBO. Conventional radiographic 
imputation methods showed that CZP effectively inhibited 
radiographic progression in PsA patients. Significantly 
fewer patients had progression with either CZP dose 
compared to PBO. CZP was shown to be effective also in 
improvements in productivity at paid work and within the 
household, and increased participation in daily activities in 
patients with PsA.56 Compared to the other anti-TNF agents, 
CZP is characterized by a different mechanism of action, 
possibly due to both structure and signal transduction. 
These features could be related to exact epitopes to which 
the anti-TNF agents bound the anti-TNF.
Conclusion
Psoriatic arthritis should be rather considered as a systemic 
disease but the major clinical characteristics are involvement 
of joints, enthesis and skin.1 Pathogenetic and clinical 
evidence suggests the role of a complex interplay between 
chronic inflammatory processes and bone remodeling.14 
Clinical guidelines and consensus statements on anti-TNF-α 
treatment are under constant revision, as data from long-
term studies are becoming continuously available. CZP is 
effective and safe for the treatment of such inflammatory 
diseases as CD38, RA46, AS, SpA48 and PsO56 and has 
been evaluated for the treatment of PsA47, with various 
interesting results. Moreover, the properties of the drug have 
several advantages for a rapid remission of the diseases. 
Subcutaneous administration confers good compliance in 
treated patients for procedures and time of administration. 
Furthermore, considering PsA as a systemic disease, with 
major involvement of both skin and joints, clinical trials 
demonstrated that CZP is efficacious in PsO, PsA, and 
SpA, as well as in radiographic progression.54,59 Moreover, 
CZP treatment should be taken into consideration not only 
in patients unresponsive to synthetic DMARDs but also in 
those patients who have failed to respond to previous anti-
TNF-α treatments, as has been demonstrated in several 
clinical trials.51,52
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